Tales from the Hydrant
by Kathy Wechsler
When one member of the family is found to have ALS, everybody in the family —
including the family dog — is affected by the disease in interesting and
unpredictable ways. Some family members adapt better than others.
The stories of Mike, Sahara and Coolidge illustrate a few of the different ways
in which your pets may respond to your physical changes brought on by ALS.
Mike (aka “the German Shedder”)
 |
|
Stephen Hallgren and Mike.
|
Stephen and Glory Hallgren live in Somerset, Wis., with their three cats, 14
chickens and a 110-pound German shepherd named Mike.
Stephen, 57, who received a diagnosis of ALS last spring, says that the
5-year-old shepherd seemed to sense the disease’s onset. Back in the summer of
2003, Hallgren fell in his front yard.
“The next summer, after my leg had healed [from the fall], Mike wouldn’t leave
my leg alone,” Hallgren says. “He kept licking my lower left leg, and that’s
where my ALS started the next fall when I first noticed a problem.”
Mike could also sense when Hallgren’s ability to walk began to deteriorate.
“He has become much more aware of my movements,” says Hallgren, who walks with
the aid of a cane. “If he is lying in a path that I need to use, all I need to
do is walk up to him and he knows that I can no longer jump over him, so he
gets up and moves.
“Another thing I have been able to convey to him since my energy has diminished
is to just go ‘psst,’ and he knows that it’s nap time,” and goes to his bed.
Hallgren misses his regular three-mile runs with Mike.
“He was more my dog, but I’m not doing much with him, and I think he’s becoming
more Glory’s dog because she takes him on walks,” he says. “I still spend the
whole day with him, so he’s pretty close to me.”
Sahara
Sterling and Jeannette Kelley of Hallsville, Mo., have a 9-year-old border
collie who’s always been a part of the family. Sahara’s loving, playful
personality changed in 2003, when Jeannette, now 73, was found to have ALS.
As Jeannette’s bulbar-onset ALS progressed, a feeding tube and then a
tracheostomy became necessary, and Sterling has become her full-time caregiver.
Jeannette’s speech is affected, and she uses a power wheelchair for mobility.
“I don’t have time to take the dog out and play with her,” Sterling says. “This
disease has pretty much ruined our relationship with Sahara because my wife has
to stay so close to the suction machine and I have to stay close to her.”
To Jeannette’s dismay, Sahara has become very reclusive. Fearful of the noises
made by Jeannette’s trach and suction machine, the black-and-white border
collie spends much of the time hiding in her kennel in the back bedroom.
“Now [Sahara] stays away from my wife because she doesn’t understand the noises
— my wife can’t talk to her,” says Sterling. “It’s changed their relationship
entirely. Sahara no longer feels comfortable in her own home.”
To give Sahara time to be an ordinary dog, the Kelleys often send her home with
friends or their two grown daughters’ families, where Sahara can be her active
self again.
Coolidge
After receiving a diagnosis of ALS in May 2004, Judson Harmon moved to St. Paul,
Minn., to live with his daughter, Kathryn Harmon Ledo, her husband, Rob Ledo,
and their 11-month-old son, John Judson Ledo.
Last year when Harmon, 71, who now uses a power wheelchair, was able to walk
with the aid of a walker, he stumbled and fell in the carpeted living room,
“probably yelling ‘Ooooff’ and muttering several rude words as I hit the
floor.”
The house was empty except for two cats, a pigeon, and Kathryn’s 3-year-old
black-and-tan American coonhound, Coolidge. Harmon, unhurt but unable to get
up, had no choice but to wait for Kathryn to return home from a short errand.
“I felt Coolidge put his head firmly under my left arm and my chest, as if to
help me rise to my feet,” says Harmon. “I immediately thought ‘How wonderful!’
and later, cynically, ‘Maybe he’ll help me find and balance my checkbook after
this.’”
By the way, Coolidge wasn’t successful at raising Harmon to his feet, but he was
good company while Harmon waited to be rescued.
“So, what was Coolidge’s purpose when he came to my side and put his head under
me as I knelt, helpless, on the living room floor? Was it to cuddle, to stop my
yelling, to see if I had any treats, mere curiosity, or to raise me up? He
didn’t say.”
|
Coolidge is protective of both Judson Harmon and his grandson John.
|
Coolidge has always been a protective and caring dog. For example, Harmon gets
his legs stretched once a week by a home health aide. When the stretching gets
painful and Harmon cries out, Coolidge often comes over, puts himself between
Harmon and the health aide, and licks Harmon’s hand, as if to ease his pain.
“Coolidge also watches out for baby John and warns Dad when his wheelchair gets
too close,” says Harmon’s daughter, Kathryn, who’s the alpha female of the
pack. “He’s given Dad a gentle nibble or even a growl when Dad has approached
the play pen too quickly.”
“When we play tug-of-war, [Coolidge] adjusts to me and doesn’t pull very hard,”
Harmon says. “He also knows he will get a high-quality scratching from me.”
Back to top
Gene ‘Flavor’ Differences Likely to Provide
Valuable Data
by Margaret Wahl
At 36, Dietrich Stephan has already completed three years of postdoctoral study
at the National Human Genome Research Institute at the National Institutes of
Health (NIH), and been an assistant professor of pediatrics, genetics,
biochemistry and biology, and an associate professor of neurology. Most
recently, he’s become director of the Neurogenomics Division of the nonprofit
Translational Genomics Research Institute (TGen) in Phoenix.
TGen has received a $652,000 grant from MDA to use state-of-the-art technology
to find the most minute differences in the genes of people with ALS compared to
people who don’t have ALS. (The grant is funded through MDA’s ALS Translational
Research Program and Augie’s Quest.)
 |
|
Alana Lysholm-Bernacchi is working at the gene chip fluidics
station. Photos by David Pantoja
|
These differences in gene “flavors,” as Stephan describes them, could unlock the
secrets to early diagnosis of ALS and provide new targets for drug development.
So far, scientists have identified five genes that can, when mutated, directly
cause ALS. But they suspect there are at least five more that can, when they
contain certain variations, predispose a person to the disease.
Small variations in a gene’s “sequence” — its chemical composition — account for
genetic differences among people. So, for instance, even though everyone has a
gene for APOE, it’s possible to have variations in the APOE sequence known as
APOE2, 3 and 4.
He expects to find similar leads in ALS by studying blood cell DNA from 1,000
people with and 1,000 people without the disease and comparing their gene
sequences.
|
Sarah Brautigam works at TGen's gene chip hybridization ovens.
|
Stephan’s TGen group will use silicon chips to look for “single nucleotide
polymorphisms,” or SNPs, a new technology that’s been developed in association
with NIH’s Human Genome Project.
“A lot of common disorders are going to topple to this technology, which has
only become available in the last six to nine months,” Stephan says.
“We’ll understand which positions in the genome predispose an individual to ALS
and then we can test them and see what their risk would be before they develop
ALS. For the future, for people who don’t have ALS yet, we can envision
developing a diagnostic test that would allow us to monitor individuals early,
diagnose them early, and put them on a to-be-developed therapy that would
intervene before the pathology gets too devastating.”
Also, he says, therapeutic targets are likely to reveal themselves. “Therapeutic
targets are what you get once you have a gene name. What I anticipate emerging
is a list of maybe five new genes, each of which becomes a new therapeutic
target that drug companies can aim their bullets at.”
Stephan expects to have identified his five targets by the end of this year,
assuming he can soon add 1,000 ALS-affected blood samples to the 1,000
unaffected samples he already has. “The core of the issue is collecting those
1,000 ALS patients. As soon as we get that done, we can rip through the rest of
it in the lab.”
Anyone with a confirmed ALS diagnosis who doesn’t have any other motor neuron
disorders can donate a blood sample to the TGen gene search by contacting any
of these sites:
Stacey Champion, Study Coordinator
Forbes Norris MDA/ALS Center
California Pacific Medical Center
San Francisco
(415) 600-3967; champis@cpmcri.org
Danielle Rowlands, Study Coordinator
University of Pittsburgh
(412) 393-9181; doerflerd@upmc.edu
Mary-Louise Spears, Study Coordinator
Methodist Neurological Institute
Houston
(731) 441-3765; mspears@tmh.tmc.edu
|
ALS RESEARCH ROUNDUP
by Margaret Wahl
Angiogenin Mutations Likely Boost ALS
Susceptibility
Mutations in the gene for angiogenin (ANG), a protein that aids in the formation
of new blood vessels, are new suspects in ALS susceptibility, says a
multinational research group whose findings were published online Feb. 26 in
Nature Genetics.
The team, led by Matthew Greenway and Orla Hardiman at the Royal College of
Surgeons in Dublin, Ireland, included Robert Brown, professor of neurology and
director of the MDA/ALS Center at Massachusetts General Hospital in Boston.
In a study of 1,629 people with ALS and 1,265 without ALS, the investigators
identified seven genetic mutations (alterations) in the ANG gene in four people
with familial ALS and 11 with no family history of the disease (sporadic ALS).
Twelve of the 15 were of Irish or Scottish descent. Only one person, a
65-year-old man, had an ANG mutation without having ALS.
Angiogenin resembles another protein, vascular endothelial growth factor (VEGF),
in that both cause the formation of new blood vessels in response to a
low-oxygen environment. Unusually low levels of VEGF have been implicated as a
possible factor in ALS.
The ANG gene variations may be risk factors only in some populations, Brown
says, although they still may be important. “The caveat from the VEGF story is
that those variants were found to be highly related to sporadic ALS only in the
Belgian population,” he says. “This has not been reproduced in other
populations.”
ANG mutations are “certainly overrepresented in ALS and certainly significantly
overrepresented in the population of Ireland and Scotland,” Brown says.
These types of variations are being sought on a large scale at the Translational
Genomics Research Institute in Phoenix (see “Gene ‘Flavor’
Differences”).
Spinal Fluid Protein Levels Useful
in ALS Diagnosis
ALS doesn’t have clear biological markers (biomarkers) of disease, which are
useful not only to diagnose a condition but as indicators of whether or not a
treatment is working.
Neurologist Merit Cudkowicz, an MDA research grantee at Massachusetts General
Hospital, and Robert Brown (see “Angiogenin Mutations”),
were part of a multi-institutional group that recently identified three spinal
fluid proteins for which levels are lower than normal in ALS. The researchers
say these protein levels may prove useful as ALS biomarkers.
The team published its results online Feb. 15 in Neurology.
These three proteins — cystatin C, VGF (not VEGF), and a third identified so far
only by its weight — were lower in concentration in the ALS patients’ spinal
fluid samples than in samples from unaffected study participants.
“Finding biomarkers that can assist physicians with diagnosis would be
beneficial,” Cudkowicz said. “Biomarkers are also important to help understand
disease mechanisms and potential treatment pathway targets, and could also
potentially help expedite clinical trials by providing ... outcome measures,”
she said, adding that the group’s results need to be replicated by others and
in larger sample sizes.
CDC Gets $900,000 to Start ALS Registry;
‘Now What?’ Is the Next Question
by Christina Medvescek
The national Centers for Disease Control and Prevention (CDC) have been
instructed by Congress to allocate $900,000 for starting a nationwide ALS
registry.
The allocation is a scant fraction of what’s needed for a registry, and there’s
no guarantee of more; in fact the project was specifically eliminated in the
2007 presidential budget proposal.
But some sort of ALS information-gathering project continues to inch forward,
though its final form is unclear. The goal is to paint a bigger picture about
the occurrence and progression of ALS in the United States, in order to further
research and treatments.
Get the Ball Rolling
Senators Harry Reid (D–Nev.) and Tom Harkin (D-Iowa) managed to insert the ALS
project into the 2006 Health and Human Services (HHS) budget signed by
President Bush in February.
Reid also co-sponsored the ALS Registry Act, which seeks to create a national
database at a cost of $25 million the first year. (See “National ALS Database Proposal Before Congress,” September 2005.) Both
registry bills (H.R. 4033 and S. 1353) currently are stuck in committee.
The HHS allocation was an attempt to get the ball rolling. However, the project
was eliminated in President Bush’s 2007 proposed HHS budget, which slashed $1.5
billion from programs like centers for traumatic brain injuries, an Alzheimer’s
disease education program and inner-city Indian health clinics.
Coordinated Effort
Now the question is: What can be done for $900,000?
Not much but something, says Dee Williamson, an epidemiologist with the CDC
Agency for Toxic Substances and Disease Registry in Atlanta.
The agency already had been counting the number of cases of ALS and multiple
sclerosis (MS) in specific areas, in hopes of developing a protocol for
gathering data nationally. However, counting cases (a surveillance project) is
far simpler and less expensive than a registry, which gathers detailed,
long-term data on disease risk factors and progression.
”We were looking for a way to tell how many people have these conditions, and to
be able to say if there’s more in one place than another,” explained
Williamson. Some data has been gathered but no report issued. (For a 2003 CDC
fact sheet on the project, see www.atsdr.cdc.gov/DHS/MS_Fact_Sheet.html.)
The CDC will meet this spring with representatives of ALS databases and ALS
groups, to discuss the situation, goals and ways to maximize resources.
Among the few existing databases is the new ALS Connections registry (www.alsconnection.com)
funded by MDA and run by Robert Miller through the Forbes Norris MDA/ALS
Research Center in San Francisco. It’s the online version of the paper-based
ALS C.A.R.E. registry (www.outcomes-umassmed.org/als/).